Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering From Metastatic Prostate Cancer

NCT03506997 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT03506997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03506997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering From Metastatic Prostate Cancer
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 2
Overall status
Unknown status
Start date
November 27, 2018
Completion date
September 1, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer